{"id":"acemetacin","rwe":[{"pmid":"41622218","year":"2026","title":"Acemetacin-loaded bilosomal gel formulations prepared using different polymers for topical application: Box-Behnken design for bilosomes formulation optimization and in vitro evaluation of the formulations.","finding":"","journal":"BMC chemistry","studyType":"Clinical Study"},{"pmid":"41155907","year":"2025","title":"Formulation of Self-Emulsifying Microemulsion for Acemetacin Using D-Optimal Design: Enteric-Coated Capsule for Targeted Intestinal Release and Bioavailability Enhancement.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"39315555","year":"2024","title":"Assessment of liver and kidney function in patients with ankylosing spondylitis on long-term non-steroidal anti-inflammatory drug therapy.","finding":"","journal":"Reumatismo","studyType":"Clinical Study"},{"pmid":"38931867","year":"2024","title":"Co-Amorphization of Acemetacin with Basic Amino Acids as Co-Formers for Solubility Improvement and Gastric Ulcer Mitigation.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"37173934","year":"2023","title":"Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.","finding":"","journal":"Cancers","studyType":"Clinical Study"}],"tags":[{"label":"acemetacin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Lactoylglutathione lyase","category":"target"},{"label":"GLO1","category":"gene"},{"label":"PTGS1","category":"gene"},{"label":"PTGS2","category":"gene"},{"label":"M01AB11","category":"atc"},{"label":"Active","category":"status"},{"label":"Ankylosing spondylitis","category":"indication"},{"label":"Rheumatism","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":86.553,"date":"","count":13,"signal":"Axial spondyloarthritis","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=87)"},{"llr":55.416,"date":"","count":16,"signal":"Spinal osteoarthritis","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=55)"},{"llr":51.875,"date":"","count":14,"signal":"Ankylosing spondylitis","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=52)"},{"llr":49.102,"date":"","count":6,"signal":"Residual urine volume increased","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=49)"},{"llr":42.755,"date":"","count":13,"signal":"Uveitis","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=43)"}],"commonSideEffects":[{"effect":"Axial spondyloarthritis","drugRate":"LLR 87","severity":"common"},{"effect":"Spinal osteoarthritis","drugRate":"LLR 55","severity":"common"},{"effect":"Ankylosing spondylitis","drugRate":"LLR 52","severity":"common"},{"effect":"Residual urine volume increased","drugRate":"LLR 49","severity":"common"},{"effect":"Uveitis","drugRate":"LLR 43","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"bay f 4975","offLabel":[],"synonyms":["Bay f 4975","TVX 1322","acemetacin","acemet","acemethacin","acemethazine","rantudil"],"timeline":[],"brandName":"Bay F 4975","ecosystem":[{"indication":"Ankylosing spondylitis","otherDrugs":[{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""}],"globalPrevalence":64000000},{"indication":"Rheumatism","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Lactoylglutathione lyase","targets":[{"gene":"GLO1","source":"DrugCentral","target":"Lactoylglutathione lyase","protein":"Lactoylglutathione lyase"},{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"}],"modality":"Small Molecule","drugClass":"acemetacin","explanation":"Think of it like a fire alarm in a burning building. The fire alarm (lactoylglutathione lyase) is triggered by the fire (inflammation), and it sends a signal to the firefighters (other enzymes) to come and put out the fire. Acemetacin blocks the fire alarm, so the firefighters don't get the signal, and the inflammation continues to burn.","oneSentence":"Acemetacin works by inhibiting the enzyme lactoylglutathione lyase, which is involved in the breakdown of certain inflammatory mediators.","technicalDetail":"Acemetacin is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits the enzyme lactoylglutathione lyase, which is involved in the breakdown of leukotrienes, potent inflammatory mediators."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/47","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACEMETACIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACEMETACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:22:09.717603","biosimilars":[],"competitors":[{"drugName":"indomethacin","drugSlug":"indomethacin","fdaApproval":"1965-06-10","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sulindac","drugSlug":"sulindac","fdaApproval":"1978-09-27","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolmetin","drugSlug":"tolmetin","fdaApproval":"1976-03-24","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"diclofenac","drugSlug":"diclofenac","fdaApproval":"1988-07-28","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"etodolac","drugSlug":"etodolac","fdaApproval":"1991-01-31","genericCount":25,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketorolac","drugSlug":"ketorolac","fdaApproval":"1989-11-30","patentExpiry":"Nov 24, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aceclofenac","drugSlug":"aceclofenac","fdaApproval":"","relationship":"same-class"}],"genericName":"acemetacin","indications":{"approved":[{"name":"Ankylosing spondylitis","source":"DrugCentral","snomedId":9631008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Care Res (Hoboken), 2016 (PMID:26713432)"},{"name":"Rheumatism","source":"DrugCentral","snomedId":396332003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"indomethacin","brandName":"indomethacin","genericName":"indomethacin","approvalYear":"1965","relationship":"same-class"},{"drugId":"sulindac","brandName":"sulindac","genericName":"sulindac","approvalYear":"1978","relationship":"same-class"},{"drugId":"tolmetin","brandName":"tolmetin","genericName":"tolmetin","approvalYear":"1976","relationship":"same-class"},{"drugId":"diclofenac","brandName":"diclofenac","genericName":"diclofenac","approvalYear":"1988","relationship":"same-class"},{"drugId":"etodolac","brandName":"etodolac","genericName":"etodolac","approvalYear":"1991","relationship":"same-class"},{"drugId":"ketorolac","brandName":"ketorolac","genericName":"ketorolac","approvalYear":"1989","relationship":"same-class"},{"drugId":"aceclofenac","brandName":"aceclofenac","genericName":"aceclofenac","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04685291","phase":"NA","title":"Ultrasound-guided Block of the Supraclavicular Nerves in Clavicular Fractures","status":"COMPLETED","sponsor":"Eckehart SCHÖLL","startDate":"2021-04-15","conditions":["Clavicular Fracture","Pain, Acute"],"enrollment":42,"completionDate":"2023-07-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003916","UNII":"5V141XK28X","CHEBI":"CHEBI:31162","INN_ID":"3664","RXNORM":"16695","UMLSCUI":"C0050409","ChEMBL_ID":"CHEMBL189171","KEGG_DRUG":"D01582","DRUGBANK_ID":"DB13783","PUBCHEM_CID":"1981","SNOMEDCT_US":"329906008","MESH_SUPPLEMENTAL_RECORD_UI":"C026784"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":142,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AB11","allCodes":["M01AB11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 1","pmid":"41622218","title":"Acemetacin-loaded bilosomal gel formulations prepared using different polymers for topical application: Box-Behnken design for bilosomes formulation optimization and in vitro evaluation of the formulations.","journal":"BMC chemistry"},{"date":"2025 Sep 27","pmid":"41155907","title":"Formulation of Self-Emulsifying Microemulsion for Acemetacin Using D-Optimal Design: Enteric-Coated Capsule for Targeted Intestinal Release and Bioavailability Enhancement.","journal":"Pharmaceutics"},{"date":"2024 Sep 24","pmid":"39315555","title":"Assessment of liver and kidney function in patients with ankylosing spondylitis on long-term non-steroidal anti-inflammatory drug therapy.","journal":"Reumatismo"},{"date":"2024 May 31","pmid":"38931867","title":"Co-Amorphization of Acemetacin with Basic Amino Acids as Co-Formers for Solubility Improvement and Gastric Ulcer Mitigation.","journal":"Pharmaceutics"},{"date":"2023 Apr 26","pmid":"37173934","title":"Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.","journal":"Cancers"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bay F 4975 is a small molecule inhibitor of the enzyme Cyclooxygenase. It is classified as a cyclooxygenase inhibitor, with synonyms including Acemetacin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}